No Data
No Data
IBio Analyst Ratings
Lucid Capital Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $6
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
IBio Names David Arkowitz and António Parada to Its Board >IBIO
Express News | Ibio Strengthens Board With Appointment of Two New Independent Directors
Press Release: IBio Strengthens Board With Appointment of Two New Independent Directors
No Data